Figure 1.

Longitudinal neutralizing antibody responses against dengue virus serotypes 1–4 (DENV1–4) and Zika virus (ZIKV) in samples obtained after ZIKV infection. The 50% focus reduction neutralization test titer (FRNT₅₀) for reverse-transcription polymerase chain reaction–confirmed ZIKV cases without (n = 10; A) or with (n = 7; B) evidence of prior DENV infection. Plasma samples obtained during the acute and convalescent (Conv) phases and 3 and 6 months after infection were evaluated by focus reduction neutralizing testing against all 4 DENV serotypes (Nicaraguan DENV1–4) and a Nicaraguan ZIKV isolate. All samples were processed in duplicate. Data for each sample set are geometric means ± standard deviations.